Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 PK Study (Food, Formulation, and PPI Effect)
NCT06619314Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calderasib in Solid tumors, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from 0 to Infinity at 48 hours, Maximum Plasma Concentration at 48 hours and 8 more. Started Sep 2023; status: completed.
02
Drugs
calderasib
03
Conditions
Solid tumors
Beyond the preview
Go deeper on NCT06619314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619314.